Anti-enolase-α autoantibodies in cancer-associated retinopathy: Epitope mapping and cytotoxicity on retinal cells

G. Adamus, D. Amundson, G. M. Seigel, M. MacHnicki

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Abstract

Patients with cancer-associated retinopathy syndrome (CAR), a progressive blinding disease related to retinal degeneration and systemic tumor outside the eye, develop autoantibodies against α-enolase. A small percentage of healthy subjects without evident tumor or visual symptoms also possess autoantibody against enolase. In these studies we examined the fine specificity of anti-enolase antibodies derived from patients with CAR and healthy individuals, using synthetic peptides covering the entire sequence of human α-enolase. Epitope mapping revealed that three binding regions of enolase within the residues 31-38 (FRAAVPSG), 176-183 (ANFREAMR) and 421-428 (AKFAGRNF) were common for all autoantibodies tested. However, pathogenic sera recognized an additional unique region, the sequence 56-63 (RYMGKGVS). There were also differences in in vitro cytotoxic activities on E1A.NR3 retinal cells and cell-death promoting activities between anti-enolase antibodies of healthy and CAR affected individuals. These studies showed that anti-enolase antibodies from patients with CAR were able to induce apoptotic cell death in E1A.NR3 retinal cells and provided a potential mechanism for retinal degeneration in humans.

Original languageEnglish (US)
Pages (from-to)671-677
Number of pages7
JournalJournal of Autoimmunity
Volume11
Issue number6
DOIs
StatePublished - Dec 1998

Keywords

  • Apoptosis
  • CAR
  • Paraneoplastic syndrome
  • Peptide
  • Retina

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Anti-enolase-α autoantibodies in cancer-associated retinopathy: Epitope mapping and cytotoxicity on retinal cells'. Together they form a unique fingerprint.

Cite this